98PD - Exon 20 mutations of the epidermal growth factor receptor (EGFR) in lung adenocarcinomas: clinicopathologic factors and response to therapy

Date 28 March 2014
Event ELCC 2014
Session Poster Discussion 2
Topics Non-Small-Cell Lung Cancer, Metastatic
Translational Research
Presenter Jarushka Naidoo
Citation Journal of Thoracic Oncology (2014) 9 (Supplement 9): S7-S52. 10.1097/JTO.0000000000000131
Authors J. Naidoo1, C.S. Sima2, M.D. Hellmann1, M.E. Arcila3, N.A. Rizvi1, H.A. Yu1
  • 1Thoracic Oncology, Memorial Sloan-Kettering Cancer Center, 10065 - New York/US
  • 2Department Of Epidemiology And Biostatistics, Memorial Sloan-Kettering Cancer Center, 10065 - New York/US
  • 3Department Of Pathology, Memorial Sloan-Kettering Cancer Center, 10065 - New York/US

Abstract

EGFR exon 20 insertions or point mutations in EGFR S768 or R776 represent 10-15% of mutations in EGFR. It is unclear whether their presence predicts response to EGFR tyrosine kinase inhibitors (TKI).